Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The firm operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The firm's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The firm's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The firm also offers Saxenda product to treat obesity. The company offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Financials in millions USD. Fiscal year is February - January.
Breakdown
TTM
03/31/2026
12/31/2025
09/30/2025
06/30/2025
03/31/2025
Revenue
327,800
96,823
79,144
74,976
76,857
78,087
Revenue Growth (YoY)
8%
24%
-8%
5%
13%
19%
Cost of Revenue
59,496
13,598
15,148
17,904
12,846
12,890
Gross Profit
268,304
83,225
63,996
57,072
64,011
65,197
Selling, General & Admin
67,384
13,217
17,438
17,880
18,849
16,112
Research & Development
52,015
10,284
14,648
15,393
11,690
10,308
Operating Expenses
119,819
23,607
32,260
33,390
30,562
26,406
Other Non Operating Income (Expenses)
--
--
--
--
--
--
Pretax Income
155,679
62,172
34,185
25,517
33,805
37,033
Income Tax Expense
33,722
13,615
7,294
5,511
7,302
7,999
Net Income
121,957
48,557
26,891
20,006
26,503
29,034
Net Income Growth
17%
67%
-5%
-27%
32%
14%
Shares Outstanding (Diluted)
4,450.68
4,450.68
4,452.15
4,446.8
4,446.7
4,446.24
Shares Change (YoY)
0%
0%
0%
0%
0%
-1%
EPS (Diluted)
27.41
10.91
6.04
4.5
5.96
6.53
EPS Growth
17%
67%
-5%
-26%
33%
15%
Free Cash Flow
31,029
12,045
-36,218
30,692
24,510
10,005
Free Cash Flow Per Share
--
--
--
--
--
--
Gross Margin
81.84%
85.95%
80.86%
76.12%
83.28%
83.49%
Operating Margin
45.29%
61.57%
40.09%
31.58%
43.52%
49.67%
Profit Margin
37.2%
50.15%
33.97%
26.68%
34.48%
37.18%
Free Cash Flow Margin
9.46%
12.44%
-45.76%
40.93%
31.89%
12.81%
EBITDA
170,173
63,154
37,298
31,439
38,282
42,621
EBITDA Margin
51.91%
65.22%
47.12%
41.93%
49.8%
54.58%
D&A For EBITDA
21,688
3,536
5,562
7,757
4,833
3,830
EBIT
148,485
59,618
31,736
23,682
33,449
38,791
EBIT Margin
45.29%
61.57%
40.09%
31.58%
43.52%
49.67%
Effective Tax Rate
21.66%
21.89%
21.33%
21.59%
21.6%
21.59%
Follow-Up Questions
What are Novo Nordisk A/S's key financial statements?
According to the latest financial statement (Form-10K), Novo Nordisk A/S has a total asset of $0, Net loss of $0
What are the key financial ratios for NVO?
Novo Nordisk A/S's Current ratio is 0, has a Net margin is 0, sales per share of $0.
How is Novo Nordisk A/S's revenue broken down by segment or geography?
Novo Nordisk A/S largest revenue segment is Victoza, at a revenue of 3,020,000,000 in the most earnings release.For geography, US Revenue is the primary market for Novo Nordisk A/S, at a revenue of 173,166,000,000.
Is Novo Nordisk A/S profitable?
no, according to the latest financial statements, Novo Nordisk A/S has a net loss of $0
Does Novo Nordisk A/S have any liabilities?
no, Novo Nordisk A/S has liability of 0
How many outstanding shares for Novo Nordisk A/S?
Novo Nordisk A/S has a total outstanding shares of 0